Chronic granulomatous disease (CGD) is an immunodeficiency disorder affecting about 1 in
250,000 individuals. The disease is caused by a lack of superoxide production by the …

Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by
defects in the genes encoding any of the NADPH oxidase components responsible for the …

Background Primary immunodeficiency diseases (PIDDs) are clinically and genetically
heterogeneous disorders thus far associated with mutations in more than 300 genes. The …

Patients with chronic granulomatous disease (CGD) suffer from recurrent, life-threatening
bacterial and fungal infections of the skin, the airways, the lymph nodes, liver, brain and …

Live-attenuated vaccines (LAVs) can protect humans against 12 viral and three bacterial
diseases. By definition, any clinical infection caused by a LAV that is sufficiently severe to …

Regulated transgene expression may improve the safety and efficacy of hematopoietic stem
cell (HSC) gene therapy. Clinical trials for X-linked chronic granulomatous disease (X-CGD) …

Chronic granulomatous Disease (CGD) is a rare innate immunodeficiency disorder caused
by mutations in one of the six genes (CYBA, CYBB, NCF1, NCF2, NCF4, and CYBC1/EROS) …

Objective—NADPH oxidase, one of the most important enzymes producing reactive oxidant
species, is suggested to play a role in experimental atherosclerosis, but its role in human …

Background Chronic granulomatous disease (CGD) is a primary immune deficiency
characterized by a defect in reactive oxygen species production. Although the effect of CGD …

Background and Aims: X-linked chronic granulomatous disease [X-CGD] due to hemizygous
mutations in CYBB is characterised by invasive bacterial and fungal infections and …